{"id":75318,"date":"2026-08-19T12:30:53","date_gmt":"2026-08-19T04:30:53","guid":{"rendered":"https:\/\/flcube.com\/?p=75318"},"modified":"2026-08-19T12:30:54","modified_gmt":"2026-08-19T04:30:54","slug":"novo-nordisk-china-launches-organizational-restructuring-merges-diabetes-and-insulin-divisions-into-hospital-business-division-creates-new-emerging-channels-division","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=75318","title":{"rendered":"Novo Nordisk China Launches Organizational Restructuring \u2013 Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Novo Nordisk A\/S China<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/NVO:NYSE\">NYSE: NVO<\/a>) announced the initiation of an <strong>organizational restructuring<\/strong> of its China operations. Following this adjustment, <strong>Novo Nordisk China&#8217;s frontline business will be reorganized into three major business units<\/strong>, signaling a strategic realignment of the Danish drugmaker&#8217;s commercial footprint in the world&#8217;s largest diabetes and obesity market.<\/p>\n\n\n\n<h2 id=\"h-restructuring-overview\" class=\"wp-block-heading\">Restructuring Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Novo Nordisk China (parent: Novo Nordisk, NYSE: NVO)<\/td><\/tr><tr><td><strong>Action<\/strong><\/td><td>Organizational restructuring initiated<\/td><\/tr><tr><td><strong>New Structure<\/strong><\/td><td>Frontline business reorganized into <strong>three major business units<\/strong><\/td><\/tr><tr><td><strong>Key Changes<\/strong><\/td><td>Division mergers, regional consolidation, new channel and marketing teams<\/td><\/tr><tr><td><strong>Announcement Date<\/strong><\/td><td>17 Aug 2026<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-business-unit-changes\" class=\"wp-block-heading\">Business Unit Changes<\/h2>\n\n\n\n<h3 id=\"h-hospital-business-division-hpd-new-merger\" class=\"wp-block-heading\">Hospital Business Division (HPD) \u2013 New Merger<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The former <strong>Diabetes Operating Division (DOD)<\/strong> and <strong>Insulin Business Division (IBD)<\/strong> have been <strong>merged<\/strong> to form the <strong>Hospital Business Division (HPD)<\/strong><\/li>\n\n\n\n<li>HPD will be responsible for <strong>integrated hospital\u2011channel operations<\/strong> covering both the <strong>insulin and GLP\u20111 product portfolios<\/strong><\/li>\n\n\n\n<li>At the regional level, the previous <strong>eight regional districts have been consolidated into six<\/strong>: North China, East China, West China, Northeast China, Southeast China, and South China<\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-emerging-channels-division-ecd-newly-established\" class=\"wp-block-heading\">Emerging Channels Division (ECD) \u2013 Newly Established<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>A new <strong>Emerging Channels Division (ECD)<\/strong> has been created, integrating <strong>retail, online healthcare management, and private medical services<\/strong> into a single organization<\/li>\n\n\n\n<li>Retail channel businesses previously under the Distribution and Retail Division (DRD) have been <strong>transferred to ECD<\/strong><\/li>\n<\/ul>\n\n\n\n<h3 id=\"h-commercial-and-broad-market-division-cbd-renamed\" class=\"wp-block-heading\">Commercial and Broad Market Division (CBD) \u2013 Renamed<\/h3>\n\n\n\n<ul class=\"wp-block-list\">\n<li>The former <strong>Distribution and Retail Division (DRD)<\/strong> has been <strong>renamed the Commercial and Broad Market Division (CBD)<\/strong><\/li>\n\n\n\n<li>CBD will continue to manage other related businesses and <strong>strengthen market expansion opportunities<\/strong> arising from the expansion of the <strong>National Essential Medicines List<\/strong><\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-marketing-and-functional-reorganization\" class=\"wp-block-heading\">Marketing and Functional Reorganization<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Function<\/th><th>Change<\/th><\/tr><\/thead><tbody><tr><td><strong>Diabetes Marketing<\/strong><\/td><td>Insulin and Injection Devices team + GLP\u20111 Diabetes Marketing team <strong>merged<\/strong> into a single <strong>Diabetes Marketing team<\/strong><\/td><\/tr><tr><td><strong>Obesity Marketing<\/strong><\/td><td>Remains <strong>independent<\/strong><\/td><\/tr><tr><td><strong>Consumer Engagement<\/strong><\/td><td>New <strong>C\u2011End Marketing team<\/strong> established to enhance consumer insights and interaction<\/td><\/tr><tr><td><strong>Government Affairs<\/strong><\/td><td>Market Access and Public Affairs (MAPA) <strong>renamed<\/strong> Government Affairs and Market Access (GAMA)<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>GLP\u20111 Era Realignment:<\/strong> Merging insulin and GLP\u20111 hospital operations into a single <strong>HPD<\/strong> reflects the shifting revenue mix toward GLP\u20111 therapies while preserving an integrated approach to Novo Nordisk&#8217;s core diabetes franchise in China.<\/li>\n\n\n\n<li><strong>Channel Shift:<\/strong> The creation of the <strong>Emerging Channels Division (ECD)<\/strong> underscores the growing importance of retail, online healthcare, and private medical services in China&#8217;s pharmaceutical distribution landscape beyond traditional hospital channels.<\/li>\n\n\n\n<li><strong>Obesity Independence:<\/strong> Keeping <strong>Obesity Marketing<\/strong> as a standalone unit signals continued strategic priority for Novo Nordisk&#8217;s weight\u2011management portfolio amid intensifying domestic competition.<\/li>\n\n\n\n<li><strong>Watch Items:<\/strong> Execution of the regional consolidation from eight to six districts, leadership appointments across the three business units, and how the restructuring impacts Novo Nordisk&#8217;s competitive posture against domestic GLP\u20111 and insulin rivals in China.<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Novo Nordisk&#8217;s organizational restructuring and business expectations in China. Actual results may differ due to risks including execution of the reorganization, market adoption, and competitive dynamics.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Novo Nordisk A\/S China (NYSE: NVO) announced the initiation of an organizational restructuring of its&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7],"tags":[148,860],"class_list":["post-75318","post","type-post","status-publish","format-standard","hentry","category-company","tag-novo-nordisk","tag-nyse-nvo"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.3) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Novo Nordisk China Launches Organizational Restructuring \u2013 Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Novo Nordisk A\/S China (NYSE: NVO) announced the initiation of an organizational restructuring of its China operations. Following this adjustment, Novo Nordisk China&#039;s frontline business will be reorganized into three major business units, signaling a strategic realignment of the Danish drugmaker&#039;s commercial footprint in the world&#039;s largest diabetes and obesity market.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=75318\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Novo Nordisk China Launches Organizational Restructuring \u2013 Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division\" \/>\n<meta property=\"og:description\" content=\"Novo Nordisk A\/S China (NYSE: NVO) announced the initiation of an organizational restructuring of its China operations. Following this adjustment, Novo Nordisk China&#039;s frontline business will be reorganized into three major business units, signaling a strategic realignment of the Danish drugmaker&#039;s commercial footprint in the world&#039;s largest diabetes and obesity market.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=75318\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-08-19T04:30:53+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-08-19T04:30:54+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75318#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75318\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Novo Nordisk China Launches Organizational Restructuring \u2013 Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division\",\"datePublished\":\"2026-08-19T04:30:53+00:00\",\"dateModified\":\"2026-08-19T04:30:54+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75318\"},\"wordCount\":511,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Novo Nordisk\",\"NYSE: NVO\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75318#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75318\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=75318\",\"name\":\"Novo Nordisk China Launches Organizational Restructuring \u2013 Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-08-19T04:30:53+00:00\",\"dateModified\":\"2026-08-19T04:30:54+00:00\",\"description\":\"Novo Nordisk A\\\/S China (NYSE: NVO) announced the initiation of an organizational restructuring of its China operations. Following this adjustment, Novo Nordisk China's frontline business will be reorganized into three major business units, signaling a strategic realignment of the Danish drugmaker's commercial footprint in the world's largest diabetes and obesity market.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75318#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=75318\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=75318#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Novo Nordisk China Launches Organizational Restructuring \u2013 Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Novo Nordisk China Launches Organizational Restructuring \u2013 Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division - Insight, China&#039;s Pharmaceutical Industry","description":"Novo Nordisk A\/S China (NYSE: NVO) announced the initiation of an organizational restructuring of its China operations. Following this adjustment, Novo Nordisk China's frontline business will be reorganized into three major business units, signaling a strategic realignment of the Danish drugmaker's commercial footprint in the world's largest diabetes and obesity market.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=75318","og_locale":"en_US","og_type":"article","og_title":"Novo Nordisk China Launches Organizational Restructuring \u2013 Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division","og_description":"Novo Nordisk A\/S China (NYSE: NVO) announced the initiation of an organizational restructuring of its China operations. Following this adjustment, Novo Nordisk China's frontline business will be reorganized into three major business units, signaling a strategic realignment of the Danish drugmaker's commercial footprint in the world's largest diabetes and obesity market.","og_url":"https:\/\/flcube.com\/?p=75318","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-08-19T04:30:53+00:00","article_modified_time":"2026-08-19T04:30:54+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=75318#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=75318"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Novo Nordisk China Launches Organizational Restructuring \u2013 Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division","datePublished":"2026-08-19T04:30:53+00:00","dateModified":"2026-08-19T04:30:54+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=75318"},"wordCount":511,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Novo Nordisk","NYSE: NVO"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=75318#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=75318","url":"https:\/\/flcube.com\/?p=75318","name":"Novo Nordisk China Launches Organizational Restructuring \u2013 Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-08-19T04:30:53+00:00","dateModified":"2026-08-19T04:30:54+00:00","description":"Novo Nordisk A\/S China (NYSE: NVO) announced the initiation of an organizational restructuring of its China operations. Following this adjustment, Novo Nordisk China's frontline business will be reorganized into three major business units, signaling a strategic realignment of the Danish drugmaker's commercial footprint in the world's largest diabetes and obesity market.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=75318#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=75318"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=75318#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Novo Nordisk China Launches Organizational Restructuring \u2013 Merges Diabetes and Insulin Divisions into Hospital Business Division, Creates New Emerging Channels Division"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75318","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=75318"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75318\/revisions"}],"predecessor-version":[{"id":75319,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/75318\/revisions\/75319"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=75318"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=75318"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=75318"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}